Advertisement

Flow Cytometric Monitoring of Drug Resistance in Human Solid Tumors

  • Awtar Krishan
  • Cheppail Ramachandran
  • Antonieta Sauerteig
Part of the Developments in Oncology book series (DION, volume 77)

Abstract

Resistance to cancer chemotherapy continues to be a major hurdle in successful management of refractory human malignancies. Drug resistance may be intrinsic or acquired after chemotherapy. Several well-known extracellular factors such as drug metabolism and pharmacokinetics may be responsible for failure of chemotherapy. However, a major reason for drug resistance resides at the cellular level and often involves cellular mechanisms which under normal conditions may have other protective and important biological roles. Tumor cell resistance is believed to be multifactorial involving altered drug transport (influx, retention and efflux), and biochemical mechanisms such as xenobiotic detoxification/ alternate metabolic pathways, and altered targets (1–3). Multiple drug resistance (MDR) has been recently described as a phenomenon in which tumor cells are resistant to a variety of unrelated natural products such as alkaloids and antibiotics used as cancer chemotherapeutic agents (1,3).

Keywords

Multiple Drug Resistance Drug Retention Flow Cytometric Study Cellular Retention MDRl Gene 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Moscow J, Cowan KH: Multidrug resistance. J. Natl. Cancer Inst. 80:14–20, 1988.PubMedCrossRefGoogle Scholar
  2. 2.
    Chabner BA, Fojo A: Multidrug resistance: P-glyco-protein and its allies-the elusive foes. J. Natl. Cancer Inst. 81:910–913, 1989.PubMedCrossRefGoogle Scholar
  3. 3.
    Kessel D (ed): Resistance to antineoplastic drugs. CRC Press Inc., Boca Raton, 1989.Google Scholar
  4. 4.
    Chen C, Chin JE, Ueda K, et al: Internal duplication and homology with bacterial transport proteins in the mdr 1 (P-glycoprotein) gene from multidrug-resistant human cells. Cell 47:381–389, 1986.PubMedCrossRefGoogle Scholar
  5. 5.
    Ueda K, Cardarelli C, Gottesman MM, Pastan I: Expression of a full-length cDNA for human “MDR1” gene confers resistance to colchicine, doxorubucin, and vinblastine. Proc. Natl. Acad. Sci. USA, 84: 3004–3008, 1987.PubMedCrossRefGoogle Scholar
  6. 6.
    van der Bliek AM, Kooiman PM, Schneioder C, Borst P: Sequence of mdr 3 cDNA encoding a human P-gly-coprotein. Gene 71:401–411, 1988.PubMedCrossRefGoogle Scholar
  7. 7.
    Chin J, Soffir R, Noonan K, et al: Structure and expression of the human MDR (P-glycoprotein) gene family. Mol. Cell Biol. 9:3808–3820, 1989.PubMedGoogle Scholar
  8. 8.
    Raymond M, Rose E, Housman DE, Gros P: Physical mapping, amplification and overexpression of the mouse mdr gene family in multidrug-resistant cells. Mol. Cell Biol. 10:1642–1651, 1990.PubMedGoogle Scholar
  9. 9.
    Shen D, Fojo A, Chin JE, et al: Human multidrug-resistant cell lines: Increased mdr-1 expression can precede gene amplification. Science 232:643–645, 1986.PubMedCrossRefGoogle Scholar
  10. 10.
    Lincke CR, van der Bliek AM, van der Schuurhuis GJ, et al: Multidrug resistance phenotype of human BRO melanoma cells transfected with a wild type human MDR-1 complementary DNA. Cancer Res. 50:1779–1785, 1990.PubMedGoogle Scholar
  11. 11.
    Ramachandran C, Yuan ZK, Huang XL, Krishan A: Doxorubucin resistance in human melanoma cells: MDR-1 and glutathione-transferase p gene expression. Biochem. Pharmacol. 45:743–751, 1993.PubMedCrossRefGoogle Scholar
  12. 12.
    Ganapathi R, Grabowski D: Enhancement of sensitivity to Adriamycin in resistant P3 88 leukemia by the calmodulin inhibitor trifluoperazine. Cancer Res. 43:3696–3699, 1983.PubMedGoogle Scholar
  13. 13.
    Krishan A, Sauerteig A, Wellham L: Flow cytometric studies on modulation of anthracycline transport by phenothiazines. Cancer Res. 45:1046–1051, 1985.PubMedGoogle Scholar
  14. 14.
    Tsuro T: Reversal of acquired resistance to vinca alkaloids and anthracycline antibiotics. Cancer Treat. Rep. 67:889–894, 1986.Google Scholar
  15. 15.
    Slater LM, Sweet P, Stupecki M, et al: Cyclosporin A corrects daunorubicin resistance in Ehrlich ascites carcinoma. Brit. J. Cancer 54:235–238, 1986.PubMedCrossRefGoogle Scholar
  16. 16.
    Howell SB, Horn D, Sanga R, et al: Comparison of the synergistic potentiation of etoposide, doxorubucin and vinblastine cytoxicity by dipyridamole. Cancer Res. 49:3178–3183, 1989.PubMedGoogle Scholar
  17. 17.
    Krishan A, Ganapathi R: Laser flow cytometric studies on intracellular fluorescence of anthracyc-lines. Cancer Res. 40:3895–3900, 1980.PubMedGoogle Scholar
  18. 18.
    Krishan A, Ganapathi R: Laser flow cytometry and cancer chemotherapy: Detection of intracellular anthracyclines by flow cytometry. J. Histochem. Cytochem. 27:1655–1656, 1979.PubMedCrossRefGoogle Scholar
  19. 19.
    Preisler H: Alteration of binding of the supravital dye Hoechst 3 3342 of human leukemic cells by adriamycin. Cancer Treat. Rep. 62:1393–1396, 1978.Google Scholar
  20. 20.
    Krishan A, Ganapathi R, Israel M: The effect of adriamycin and analogs on the nuclear fluorescence of propidium iodide stained cells. Cancer Res. 38:3656–3662, 1978.PubMedGoogle Scholar
  21. 21.
    Krishan A, Sridhar KS, Davilla E, et al: Patterns of anthracycline retention modulation in human tumor cells. Cytometry 8:306–314, 1987.PubMedCrossRefGoogle Scholar
  22. 22.
    Sridhar KS, Krishan A, Samy TSA, et al: Prochlorperazine as a doxorubucin-efflux blocker: Phase I clinical and pharmacokinetics studies. Cancer Chemother. Pharmacol. 31:423–430.Google Scholar
  23. 23.
    Krishan A, Sauerteig A, Stein J: A comparison of three commercially available antibodies for flow cytometric monitoring of P-glycoprotein expression in tumor cells. Cytometry 12:731–742, 1991.PubMedCrossRefGoogle Scholar
  24. 24.
    Meister A, Anderson M: Glutathione. Annual Rev. Biochem. 52:711–760, 1983.CrossRefGoogle Scholar
  25. 25.
    Kramer R, Zakher J, Kim G: Role of the glutathione redox cycle in acquired and de novo multidrug resistance. Science 241:694–697, 1988.PubMedCrossRefGoogle Scholar
  26. 26.
    Nair S, Singh SV, Samy TSA, Krishan A: Anthracycline resistance in murine leukemic P3 88 cells: Role of drug efflux and glutathione related enzymes. Biochem. Pharmacol. 39:723–728, 1990.PubMedCrossRefGoogle Scholar
  27. 27.
    Jakoby W, Habig W: In: Enzymatic basis of detoxification, W Jakoby (ed), Academic Press, NY, 2:63–94, 1980.Google Scholar
  28. 28.
    Mannervik A, Alin P, Guthenberg C: Identification of three classes of cytosolic glutathione transferase common to several mammalian species: Correlation between structural data and enzymatic properties. Proc. Natl. Acad. Sci. USA 82:7202–7206, 1985.PubMedCrossRefGoogle Scholar
  29. 29.
    Litwack G, Ketterer B, Arias I: Ligandin: A hepatic protein which binds steroids, bilirubin, carcinogens and a number of exogenous organic anions. Nature 234:466–467, 1971.PubMedCrossRefGoogle Scholar
  30. 30.
    Green J, Vistica D, Young R: Potentiation of mephalan cytotoxicity in human ovarian cancer cell lines by glutathione depletion. Cancer Res. 44: 5427–5431, 1984.PubMedGoogle Scholar
  31. 31.
    Russo A, Mitchell JB: Potentiation and protection of doxorubucin cytotoxicity by cellular glutathione modulation. Cancer Treat. Rep. 69:12 93–1296, 1985.Google Scholar
  32. 32.
    Hromas RA, Andrews PA, Murphy MP, Burns PC: Gluta-thione depletion reverses cisplatin resistance in murine L1210 leukemia cells. Cancer Lett. 34:9–13, 1987.PubMedCrossRefGoogle Scholar
  33. 33.
    Rice GC, Bump EA, Shrieve DC, et al: Quantitative analysis of cellular glutathione by flow cytometry utilizing monochlorobimane: Some applications to radiation and drug resistance. Cancer Res. 46: 6105–6110, 1986.PubMedGoogle Scholar
  34. 34.
    Shrieve DC, Bump EA, Rice GC: Heterogeneity of cellular glutathione among cells derived from a murine fibrosarcoma or a human renal cell carcinoma detected by flow cytometry. J. Biol. Chem. 263: 14107–14114, 1988.PubMedGoogle Scholar
  35. 35.
    Nair S, Singh SV, Krishan A: Flow cytometric monitoring of glutathione content and anthracycline retention in tumor cells. Cytometry 12:336–342, 1991.PubMedCrossRefGoogle Scholar

Copyright information

© Kluwer Academic Publishers 1996

Authors and Affiliations

  • Awtar Krishan
  • Cheppail Ramachandran
  • Antonieta Sauerteig

There are no affiliations available

Personalised recommendations